Pre-eclampsia First Trimester Screening

First-trimester pre-eclampsia screening is an advanced predictive evaluation designed to identify pregnancies where the placenta may not be functioning optimally. Although high blood pressure usually manifests in the second or third trimester, the 'seeds' of pre-eclampsia are sown during the first 12 weeks of pregnancy when the placenta embeds into the uterine wall.

If the placental blood vessels (spiral arteries) do not transform correctly, the placenta remains under stress, releasing factors into the mother's bloodstream that lead to systemic inflammation and vascular damage. This is what we call pre-eclampsia. In our Unit, we moved beyond basic risk factor checklists and utilize the 'Triple Test' during the 12-week window. This evaluates:

1. Mean Arterial Pressure (MAP): Blood pressure measured in both arms using a specific clinical protocol.
2. Uterine Artery Doppler: Ultrasound technology to measure the resistance of blood flow to the placenta.
3. Maternal Biochemistry: Measuring Placental Growth Factor (PlGF), a protein that directly reflects placental health.

By integrating these three markers, we can predict pre-eclampsia requiring delivery before 34 weeks with approximately 90% sensitivity.

Pre-eclampsia risk should be assessed early in pregnancy. Depending on the protocol and resources available, assessment may combine maternal history and characteristics with blood pressure, uterine-artery Doppler, and biochemical markers. Risk is higher with factors such as previous pre-eclampsia, multifetal pregnancy, chronic hypertension, kidney disease, diabetes, or autoimmune disease, but the absence of recognised factors does not eliminate risk. The result informs discussion of prevention and surveillance; it does not diagnose pre-eclampsia.

The screening procedure is seamlessly integrated into your 12-week Nuchal Translucency visit. It is a precise, three-step clinical assessment:

• Precision Biometrics: Your blood pressure is taken twice in each arm by our trained staff using validated equipment. We calculate the Mean Arterial Pressure (MAP), which is a more stable indicator of vascular health than a single reading.
• Advanced Doppler Ultrasound: Our MFM subspecialists use color Doppler to visualize the uterine arteries. We measure the 'Pulsatility Index' (PI) to see how much resistance the blood faces as it tries to enter the placenta. High resistance is a major warning sign.
• Placental Biochemistry: A blood sample is analyzed for PlGF. A healthy, well-embedding placenta produces high levels of PlGF; low levels indicate the placenta is under stress.

A result is considered 'high risk' if the ratio is 1 in 100 or higher. This doesn't mean you have pre-eclampsia; it means you have entered a group that requires active prevention.

The primary power of this screening is that it identifies a preventable risk. If you are identified as high-risk, we have a clear, evidence-based intervention plan:

• Low-Dose Aspirin (150mg): The landmark ASPRE trial proved that starting low-dose aspirin (ideally 150mg at night) before 16 weeks of pregnancy reduces the risk of early-onset pre-eclampsia by 62% and preterm pre-eclampsia by over 80%. Crucially, the aspirin must start early to assist the placenta as it embeds.
• Vigilant Monitoring: High-risk patients receive more frequent blood pressure checks and 'Placental Function' scans at 24, 28, and 32 weeks. These specialized scans monitor fetal growth and blood flow to ensure the baby is thriving and that we can plan a controlled, safe delivery if the placental function begins to decline.

The clinical outcome of successful pre-eclampsia screening is the prevention of emergencies. By using aspirin and proactive monitoring, we aim to extend the pregnancy as close to term as possible. Every day gained in the womb is a day that reduces the need for the Neonatal Intensive Care Unit (NICU).

For the mother, early management prevents the dangerous complications of hypertensive crisis, such as HELLP syndrome, placental abruption, or seizures (eclampsia). Our goal is to transform a high-risk pregnancy into a well-managed, predictable journey that results in a healthy mother and a thriving baby. In many cases, we can completely prevent the most severe forms of the disease through this early first-trimester intervention.

This screening must be performed between 11 weeks and 13 weeks + 6 days. Outside of this window, the Doppler measurements are no longer predictive of development, and the 'window of opportunity' for aspirin becomes less effective.

If you have chronic hypertension, kidney disease, or a history of severe pre-eclampsia, you should seek a direct referral to the Maternal Fetal Medicine Unit as soon as your pregnancy is confirmed. We provide the specialized PlGF testing and Uterine Artery Doppler precision that are required for a true FMF-accredited risk assessment. Waiting until later in the second trimester to check your blood pressure is simply too late for effective prevention.